Cocaine Rehab Cost in Massachusetts: Contingency Management, Pricing, 2026 Reality
Cocaine rehab in Massachusetts costs $16,000 to $50,000 for a 30-day inpatient program without insurance, or $6,000 to $20,000 out-of-pocket with PPO insurance. Unlike opioids and alcohol, cocaine use disorder has no FDA-approved medication — contingency management (CM) is the most evidence-based treatment. Cocaine was present in 56% of MA opioid overdose deaths in 2023 — one of the highest polysubstance rates in the nation, indicating extensive overlap between cocaine and opioid mortality. Fentanyl-contaminated cocaine is especially dangerous for stimulant-only users with no opioid tolerance. MassHealth covers the full continuum at $0 for 2.3 million enrollees; McLean Hospital (Harvard-affiliated) is a national leader in cocaine pharmacotherapy research.
Massachusetts cocaine treatment in 2026 is shaped by three realities: no FDA-approved MAT, exceptionally high polysubstance use (56% of opioid deaths involve cocaine), and comprehensive state policy infrastructure. This guide combines MA’s policy strengths (Chapter 258, MassHealth no-prior-auth MAT, BSAS safety net, BMC Project TRUST) with cocaine-specific clinical realities (CM gold-standard, fentanyl-contaminated cocaine risk, academic research access).
The MA Cocaine Reality
No FDA-Approved MAT for Cocaine (2026)
The clinical honesty competitors avoid: there is no FDA-approved medication for cocaine use disorder. Unlike opioid UD (buprenorphine, methadone, Vivitrol) or alcohol UD (naltrexone, acamprosate, disulfiram), stimulant UD has no pharmacologic mainstay.
56% Cocaine Presence in MA Opioid Deaths
MA DPH 2023: cocaine present in 56% of opioid overdose deaths — one of the highest polysubstance rates in the nation. More than half of MA opioid fatalities involve cocaine co-use. This means MA has exceptionally high overlap between stimulant UD and OUD.
Fentanyl-Contaminated Cocaine Risk
MA’s drug checking program has documented fentanyl contamination of cocaine samples. For cocaine users with no opioid tolerance, fentanyl-laced cocaine can cause fatal respiratory depression.
What Works: Contingency Management
- Retention rates 70%+ in some studies
- Medium-to-large effect sizes in meta-analyses
- Strongest psychosocial evidence for stimulant UD
CM + Cocaine Research Leadership in MA
Massachusetts academic centers are national leaders:
- McLean Hospital (Harvard) — pioneer in cocaine pharmacotherapy research
- Massachusetts General Hospital — addiction medicine research
- Boston Medical Center — Project TRUST + research
- UMass Memorial Worcester — clinical trials
Why Massachusetts Is Different for Cocaine Treatment
1. Highest Polysubstance Rate (56% Cocaine in Opioid Deaths)
Requires sophisticated integrated treatment approach.
2. MassHealth No-Prior-Auth MAT for Co-Occurring OUD
Enables rapid opioid MAT for the many MA cocaine patients with OUD co-occurrence.
3. World-Class Academic Research (McLean Hospital)
McLean (Harvard-affiliated) has been a national leader in cocaine pharmacotherapy research for decades. Clinical trials offer MA residents access to experimental treatments.
4. Chapter 258 — State Law Beyond Federal Parity
Mandates comprehensive SUD coverage applying to stimulant UD.
5. BSAS Tiered Safety Net
ATS/CSS/TSS/residential — free for uninsured.
6. State Drug Checking Program
Documents fentanyl contamination of cocaine supply.
7. Fentanyl Test Strip Legalization
First state. Protects stimulant-only users from fatal contamination exposure.
8. BMC Project TRUST Low-Threshold Model
Particularly valuable for polysubstance patients — integrated CM + opioid MAT + harm reduction.
9. Section 35 Civil Commitment Option
Family intervention pathway (up to 90 days).
10. Lowest Uninsured Rate in Nation (3.2%)
Near-universal coverage access.
For full Massachusetts regulatory context, see rehab cost in Massachusetts. For cocaine-specific clinical treatment nationally, see cocaine rehab cost.
Cocaine Rehab Cost in MA: 2026 Breakdown
| Level of Care | Duration | Without Insurance | With PPO |
|---|---|---|---|
| Medical observation / crash monitoring | 5–7 days | $1,500 – $4,900 | $500 – $2,450 |
| Inpatient residential (standard) | 30 days | $16,000 – $30,000 | $6,000 – $15,000 |
| Inpatient residential (mid-tier) | 30 days | $30,000 – $42,000 | $12,000 – $20,000 |
| Boston / North Shore luxury | 30 days | $45,000 – $80,000+ | Capped at OOP max |
| Partial hospitalization (PHP) | 4–6 weeks | $6,000 – $20,000 | Capped at OOP max |
| Intensive outpatient with CM | 8–12 weeks | $4,000 – $12,000 | Capped at OOP max |
| Standard outpatient with CM | 6–12 months | $2,000 – $8,000 | Capped at OOP max |
| Contingency management incentives | 12–24 weeks | $300 – $1,000 total | Increasingly covered |
MassHealth covers all at $0.
Fentanyl-Contaminated Cocaine: Particular MA Risk
MA’s drug supply environment (90% fentanyl in opioid deaths, 34% xylazine in street samples) means fentanyl contamination of the cocaine supply is a real and documented risk. For cocaine users with no opioid tolerance, this can be fatal.
MA Harm Reduction Response
- MA DPH Naloxone Distribution — statewide free
- Fentanyl test strips — legalized at state level (first state)
- MA DPH Drug Checking Program — documents cocaine contamination
- Authorized MA SSPs — distribute test strips + naloxone to stimulant users
- MA Good Samaritan Law — strong 911-caller protection
Treatment Implications
Cocaine patients with fentanyl-contaminated exposure are effectively dual-substance patients. MA treatment programs screen for both. MassHealth’s no-prior-auth opioid MAT policy enables rapid access for polysubstance patients.
For full fentanyl mechanics in MA, see fentanyl rehab cost in Massachusetts.
Cocaine Withdrawal and the “Crash”
Cocaine withdrawal is not medically dangerous like alcohol or benzo withdrawal — but psychologically intense.
| Phase | Duration | Clinical Picture |
|---|---|---|
| Crash | 24–72 hours | Fatigue, depression, appetite increase |
| Acute withdrawal | 1–2 weeks | Anhedonia, cravings, sleep disturbance |
| Subacute | 2–10 weeks | Cravings persist |
| PAWS | Months | Episodic cravings |
What Detox Includes in MA
- 24/7 nursing observation
- Psychiatric assessment for suicidality (crash depression can be severe)
- Sleep aids, nutritional support
- Cardiac screening (cocaine can cause MI, arrhythmia, cardiomyopathy)
- Co-occurring substance management (alcohol, opioid with rapid MAT access)
- Screening for fentanyl exposure
- Warm handoff to CM
Polysubstance Treatment: The MA Reality
MA’s 56% cocaine-in-opioid-deaths rate means most MA cocaine patients are polysubstance:
- Cocaine + fentanyl — driving 56% polysubstance rate
- Cocaine + alcohol — “speedball”; high cardiac risk
- Cocaine + opioid — classic speedball; MA high-risk pattern
- Cocaine + benzodiazepines
- Cocaine + methamphetamine — rising in MA
MA integrated polysubstance approach:
- CM for stimulants
- Alcohol MAT if AUD (naltrexone/Vivitrol)
- Opioid MAT (no prior auth at MassHealth — rapid access)
- Xylazine protocols when contamination detected
- Treatment of co-occurring psychiatric conditions
- Bernese induction at academic centers
BMC Project TRUST’s integrated model is particularly well-suited to MA polysubstance patients.
Contingency Management in MA
Where CM Is Available
- McLean Hospital — Harvard-affiliated research programs
- Mass General Hospital Addiction Medicine
- Boston Medical Center Project TRUST — integrated with opioid MAT
- UMass Memorial Worcester
- Community providers — ask specifically
- BSAS-contracted providers — varies
- MassHealth Managed Care — coverage expanding
- Commercial insurers — under Chapter 258 + MHPAEA, increasingly covered
Off-Label Pharmacotherapy Research at MA Academic Centers
- McLean Hospital Division of Alcohol, Drugs, and Addiction — pioneer
- Mass General Hospital
- Boston Medical Center
- UMass Memorial Worcester
Agents: topiramate, bupropion, modafinil, naltrexone + bupropion combination, disulfiram, novel compounds. Clinical trials offer free access to experimental medications with full monitoring.
Cocaine Treatment Length in MA
- Medical observation/crash support (5–7 days)
- Residential or PHP (30–90 days)
- IOP with contingency management (8–12 weeks)
- Standard outpatient with continued CM (6–12 months)
- Recovery support and co-occurring treatment (ongoing)
NIDA recommends minimum 90 days. CM peaks in first 12–24 weeks. Under Chapter 258, MA insurers cannot impose arbitrary day caps.
How Do Bay Staters Afford Cocaine Rehab?
1. MassHealth (2.3 Million Enrollees)
Full continuum + CM at $0. No prior auth for co-occurring OUD MAT.
2. Private Commercial Insurance
BCBS Massachusetts, Harvard Pilgrim/Point32Health, Tufts, MGB Health Plan, UHC, Aetna, Cigna.
3. BSAS-Funded Programs
ATS/CSS/TSS/residential — free for uninsured.
4. MA Health Connector
Subsidized marketplace plans.
5. Major MA Nonprofits
Gavin Foundation, AdCare, Gosnold, Spectrum, High Point.
6. BMC Project TRUST
Low-threshold + polysubstance integration.
7. McLean Hospital Research Programs
Clinical trials — free access to experimental treatments.
8. Faith-Based Free Residential
Salvation Army ARCs, Teen Challenge MA.
9. FQHCs (50+ Statewide)
10. Section 35 (Court-Ordered)
Family intervention pathway.
Choosing an MA Cocaine Rehab
Verification questions:
- Is the facility BSAS-licensed?
- Is the facility accredited?
- Do you offer contingency management?
- How do you handle polysubstance use — especially cocaine + opioid?
- Do you screen for fentanyl exposure?
- Is the facility in-network for my plan?
- Are you a BSAS-funded provider (if uninsured)?
- What’s the outpatient / IOP continuation plan?
- What’s my deductible and OOP max, and what’s met year-to-date?
Massachusetts Cocaine Resources
State Resources
- MA Substance Use Helpline: 1-800-327-5050 (24/7)
- MA DPH / BSAS: mass.gov/substance-addiction-services
- SAMHSA: 1-800-662-4357
- 988 Suicide & Crisis Lifeline: 988
Harm Reduction (National Leader)
- MA DPH Naloxone Distribution — free, statewide
- MA DPH Drug Checking Program
- Fentanyl test strips — legalized at state level
- Authorized MA SSPs
- Boston AHOPE — long-standing Boston harm reduction
Major MA Counties
- Suffolk (Boston): 617-534-5395
- Middlesex: 617-349-6100
- Worcester: 508-799-1170
- Hampden (Springfield): 413-787-6797
Support Groups
- Cocaine Anonymous Massachusetts — active meetings
- AA Massachusetts — co-occurring alcohol use
- SMART Recovery Massachusetts
- Massachusetts Organization for Addiction Recovery (MOAR)
Final Thoughts
Massachusetts cocaine treatment in 2026 faces the clinical limitation of no FDA-approved MAT, addressed through increasingly available contingency management and McLean Hospital’s national leadership in cocaine pharmacotherapy research. MA’s 56% cocaine-in-opioid-deaths rate means polysubstance treatment is essential — and MassHealth’s no-prior-auth MAT policy enables rapid opioid MAT for the many cocaine patients with co-occurring OUD. BMC Project TRUST, academic medical center research, MA’s harm reduction leadership, and BSAS safety net collectively provide strong cocaine treatment infrastructure.
Five steps:
- Call MA Substance Use Helpline: 1-800-327-5050
- Check MassHealth — $0 coverage including CM and co-occurring OUD MAT
- Ask about contingency management at the admitting facility
- Screen for polysubstance use — especially fentanyl-contaminated cocaine
- Carry naloxone + use fentanyl test strips (legal at state level)
For broader context, see rehab cost in Massachusetts, cocaine rehab cost, alcohol rehab cost in Massachusetts, fentanyl rehab cost in Massachusetts, and medical detox cost.
Sources
- Massachusetts Department of Public Health. “Opioid-Related Overdose Deaths Report.” 2023.
- MA DPH Drug Checking Program. 2023–2024.
- MassHealth. “Behavioral Health Services.” 2024.
- BSAS (Bureau of Substance Addiction Services). 2024.
- Boston Medical Center Project TRUST. 2024.
- McLean Hospital Division of Alcohol, Drugs, and Addiction. “Cocaine Pharmacotherapy Research.” 2024.
- MA Opioid Recovery and Remediation Fund. 2024.
- Massachusetts General Laws Chapter 258.
- Massachusetts General Laws Chapter 123, Section 35.
- National Institute on Drug Abuse. “Cocaine Research Report.” 2024.
- Higgins ST, et al. “Contingency Management for Stimulant Use Disorder: A Systematic Review.” Addiction. 2024.
- American Society of Addiction Medicine. “Clinical Guidance on Stimulant Use Disorder.” 2023.
- U.S. Department of Labor. “Mental Health Parity and Addiction Equity Act Final Rule (September 2024).”
- SAMHSA Behavioral Health Treatment Services Locator. 2025. https://findtreatment.samhsa.gov/
Cocaine Treatment in Massachusetts — Is Your Plan Enough?
Even with insurance, many people discover their plan doesn't cover residential treatment at the level they need. A broker who specializes in behavioral health coverage can review your situation and find a plan that works.
Call 1-866-454-9577Free Consultation · No Obligation
Prodest Insurance Group is a licensed, independent health insurance brokerage. Calling the number above connects you with a licensed insurance agent, not a treatment facility. Insurance placement is a separate service from treatment referral.
Frequently Asked Questions
How much does cocaine rehab cost in Massachusetts?
Cocaine rehab in Massachusetts costs $16,000–$50,000 for 30 days of inpatient treatment without insurance, or $6,000–$20,000 out-of-pocket with PPO insurance (capped at the 2026 OOP max of $7,000–$9,500). Detox typically runs 5–7 days because cocaine withdrawal is primarily psychological rather than medically dangerous. Contingency management (CM), the most evidence-based treatment for cocaine use disorder, is offered by Massachusetts commercial insurers and MassHealth at eligible providers. Boston luxury programs run $45,000–$80,000+; Western MA and Worcester programs $16,000–$28,000 (30–40% below Boston). MassHealth (2.3 million enrollees) covers the full continuum at $0. For uninsured residents, BSAS-funded programs provide a safety net.
Is there FDA-approved medication for cocaine addiction?
No. As of 2026, there is no FDA-approved medication-assisted treatment specifically for cocaine use disorder. What Massachusetts clinicians use: (1) contingency management (CM) as the gold-standard evidence-based intervention — retention rates reach 70%+ in some studies; (2) cognitive behavioral therapy (CBT) and motivational interviewing; (3) off-label pharmacotherapy being actively studied at MA academic centers — McLean Hospital (Harvard-affiliated) is a national leader in cocaine pharmacotherapy research, plus Mass General Hospital, Boston Medical Center, and UMass Memorial. Agents studied include topiramate, bupropion, modafinil, naltrexone + bupropion combination, and disulfiram. (4) Treatment of co-occurring depression, anxiety, or ADHD that often drives stimulant use. MassHealth's no-prior-auth MAT policy makes opioid MAT readily available for the many MA cocaine patients with co-occurring OUD (cocaine present in 56% of MA opioid deaths).
Is cocaine contaminated with fentanyl in Massachusetts?
Yes, and the risk is especially high in Massachusetts given the state's high fentanyl + xylazine prevalence in the broader drug supply. Massachusetts Department of Public Health 2023 data show cocaine present in 56% of opioid overdose deaths — one of the highest polysubstance rates in the nation, indicating extensive overlap between cocaine use and opioid-involved mortality. The MA DPH drug checking program has documented fentanyl contamination of cocaine samples, with xylazine also detected in some stimulant supply. Fentanyl-contaminated cocaine is especially dangerous because cocaine users typically have no opioid tolerance — a fentanyl-laced bag can cause fatal respiratory depression. MA's harm reduction infrastructure (fentanyl test strips legalized, state drug checking program, authorized SSPs, MA DPH Naloxone Distribution) is among the most comprehensive in the nation for helping stimulant-only users avoid fatal contamination exposure.
Does MassHealth cover cocaine rehab?
Yes, comprehensively. MassHealth covers the full cocaine use disorder treatment continuum at $0 cost for 2.3 million Massachusetts enrollees through managed care plans (BMC HealthNet Plan, Tufts Health Plan/Point32Health, Mass General Brigham Health Plan, Fallon Health, WellSense): Acute Treatment Services (ATS — medical observation, 3–7 days), Clinical Stabilization Services (CSS), Transitional Support Services (TSS), inpatient residential treatment, PHP, IOP, standard outpatient, and evidence-based psychotherapies (CBT, CM, MI). MassHealth coverage of contingency management for stimulant UD is expanding. The no-prior-auth MAT policy is particularly valuable for MA cocaine patients with co-occurring OUD (cocaine present in 56% of MA opioid deaths) — enabling rapid buprenorphine access. Apply at [mahealthconnector.org](https://www.mahealthconnector.org/) or 1-800-841-2900.
What is contingency management and does it work for cocaine?
Contingency management (CM) is an evidence-based behavioral treatment that provides small tangible incentives (gift cards, vouchers, prize drawings) contingent on negative drug tests or attendance at treatment sessions. For stimulant use disorder specifically, CM has the strongest evidence base of any psychosocial intervention — retention rates reach 70%+ in some studies. Massachusetts academic medical centers are national leaders: McLean Hospital (Harvard-affiliated) has been pioneering CM and cocaine pharmacotherapy research for decades; Mass General Hospital, Boston Medical Center Project TRUST, and UMass Memorial all offer CM programs. MassHealth coverage of CM for stimulant UD is expanding. Under Chapter 258 + the 2024 federal MHPAEA final rule, MA commercial insurers are increasingly expected to cover CM. Ask facilities and outpatient providers whether CM is offered.
How does MA handle cocaine + opioid polysubstance?
Massachusetts has one of the most sophisticated polysubstance treatment infrastructures in the nation, critical given that cocaine was present in 56% of MA opioid overdose deaths in 2023 — meaning more than half of MA's opioid fatalities involve cocaine co-use. The MA DPH drug checking program documents fentanyl-contaminated cocaine, and many MA patients have both stimulant and opioid use disorders. MA integrated polysubstance approach: (1) simultaneous CM for stimulants + opioid MAT (enabled by MassHealth's no-prior-auth policy); (2) Bernese induction at MA academic centers for patients with both cocaine and fentanyl exposure; (3) xylazine protocols when contamination documented; (4) BMC Project TRUST's low-threshold integrated model especially valuable for polysubstance patients; (5) McLean Hospital research on co-occurring SUD + psychiatric conditions. MA's drug checking data informs facility protocols — MA treatment programs have some of the most evidence-based polysubstance protocols in the country.
How do Bay Staters in the coverage gap access cocaine treatment?
Massachusetts has an exceptionally strong coverage gap pathway given MA's 3.2% uninsured rate (lowest in the nation). For those without MassHealth or private insurance: (1) BSAS-funded programs — ATS (Acute Treatment Services), CSS (Clinical Stabilization Services), TSS (Transitional Support Services), and residential — provide free cocaine treatment statewide; call the MA Substance Use Helpline at 1-800-327-5050; (2) MA Health Connector marketplace plans are subsidized; (3) Major MA nonprofits including Gavin Foundation (Boston), AdCare Hospital (Worcester), Gosnold (Cape Cod), Spectrum Health Systems (Central MA), and High Point Treatment Center (Plymouth) offer sliding-scale fees; (4) Salvation Army ARCs (Boston + others) provide free 6–12 month residential; (5) 50+ FQHCs offer cocaine treatment on sliding fee scales; (6) Boston Medical Center Project TRUST's low-threshold model; (7) Section 35 court-ordered treatment (for families). The MA Substance Use Helpline is the best starting point — 24/7 free referrals.
What off-label medications are being studied for cocaine at MA academic centers?
Massachusetts is home to some of the nation's leading cocaine pharmacotherapy research. McLean Hospital (Harvard-affiliated, Belmont) has been a pioneer in cocaine pharmacotherapy research for decades — the Division of Alcohol, Drugs, and Addiction studies novel treatments. Agents being studied: (1) topiramate — anticonvulsant with modest evidence for reducing cocaine use; (2) bupropion — antidepressant, useful with co-occurring depression; (3) modafinil — mixed evidence but actively studied; (4) naltrexone + bupropion combination — early evidence; (5) disulfiram — dopamine metabolism effects; (6) novel compounds from McLean's neuroscience research. Mass General Hospital, Boston Medical Center, and UMass Memorial also offer clinical trials for stimulant use disorder. Patients can access experimental medications through clinical trials — often at no cost with full monitoring. Ask addiction medicine clinicians about trial availability.
What is the Section 35 pathway for cocaine?
Section 35 (MA General Laws Chapter 123) is Massachusetts's civil involuntary commitment statute allowing courts to order involuntary substance abuse treatment for up to 90 days — including for cocaine use disorder. Spouse, blood relative, guardian, police officer, or physician can petition when substance use creates likelihood of serious harm. For cocaine specifically, Section 35 may be used when: (1) cocaine + alcohol or opioid polysubstance creates cardiac or overdose risk; (2) fentanyl-contaminated cocaine exposure has occurred; (3) psychiatric decompensation from cocaine use requires intervention; (4) families have exhausted voluntary intervention. Process: file petition at district court → hearing same/next day → physician/psychologist examination → commitment up to 90 days at BSAS-licensed facility. Filing is free (no fee); court-appointed attorney provided. Section 35 for stimulant-only patients has been less common than for opioid/alcohol UDs; some advocates note limited effectiveness for stimulants in particular.